Literature, news and videos pertinent to
The Andy Martin Rare Cancers Program
- First-ever phase 3 clinical trial opens for patients with advanced anal cancer
- New Treatments for Rare Cancers Getting Quick Approval Under 'Orphan Drug' Process - Healthline.com
- Therapy for Rare Cancers Receives FDA Approval Following Trials at Penn's Abramson Cancer - Penn Medicine News, July 31, 2018
- Rare Cancers Present Unique Challenges - American Cancer Society, May 24, 2017
The Andy Martin Rare Cancers Program is a vital part of ICAN's Cancer Patient Advocacy and Clinical Trials Program Advocacy Services.
For more information about this special program, please click on...
We also accept PayPal™
paypal.me/ICANadvocacy
Federal Tax I.D.: EIN 86-0818253